EurekAlert! Cancer Research - News Releases

News Releases

Updates every hour. Last Updated: 17-Jul-2025 18:11 ET (17-Jul-2025 22:11 GMT/UTC)

Why you need to subscribe to NFCR’s new podcast, “All Things Cancer”

National Foundation for Cancer Research
Business Announcement

The National Foundation for Cancer Research (NFCR) is excited to announce the official launch of its groundbreaking new podcast, All Things Cancer, premiering on February 11, 2025.

New study offers hope to patients with advanced liver cancer, cirrhosis

Boston University School of Medicine
Peer-Reviewed Publication

In a new study published in the British Journal of Surgery, researchers describe successful tumor removal through the use of immunotherapy and targeted radiation therapy (TARE), in a patient previously considered ineligible for the procedure.

E64FC26, a protein disulfide isomerase inhibitor, ameliorates articular cartilage damage and disease severity in a mouse model of rheumatoid arthritis

Xia & He Publishing Inc.
Peer-Reviewed Publication

Protein disulfide isomerases (PDIs) are essential enzymes that facilitate the proper folding of proteins and maintain protein quality within the endoplasmic reticulum. Dysregulation of PDIs has been correlated with numerous disorders, including cancer and rheumatoid arthritis (RA). E64FC26 (EFC), a small molecule that inhibits a wide range of PDI family members, has shown promise as a therapeutic agent in oncology. However, its effects on RA have not yet been studied. This research investigates the efficacy of EFC as a potential treatment for RA.

Journal: Exploratory Research and Hypothesis in Medicine

When blood cancer starts to spread

Max Delbrück Center for Molecular Medicine in the Helmholtz Association
Peer-Reviewed Publication

When blood cancer cells break through the bone and multiply, tumor cells become dangerously diverse and the immune response in the region changes, researchers from Berlin and Heidelberg report in Science Immunology. The detailed insights into cancer progression could advance diagnostics and treatment.

Journal: Science Immunology

Rare case of donor cell-derived blood cancer discovered nine years after stem cell transplant

Impact Journals LLC
Peer-Reviewed Publication

BUFFALO, NY - February 10, 2025 – A new case report was published in Volume 16 of Oncotarget on February 5, 2025, titled “A case report of donor cell–derived hematologic neoplasms 9 years after allogeneic hematopoietic cell transplantation."

Journal: Oncotarget

Does pain affect cancer survivors’ use of non-opioid substances?

Wiley
Peer-Reviewed Publication

Experiencing pain may increase the odds that cancer survivors will use cigarettes and cannabis, according to a recent study published by Wiley online in CANCER.

Journal: Cancer

Candidate genes in canine hepatocellular carcinoma for molecular targeted therapy

Osaka Metropolitan University
Peer-Reviewed Publication

Unresectable canine hepatocellular carcinoma (HCC) has limited nonsurgical treatment options. Sorafenib is a targeted therapy for unresectable canine HCC. However, there are limited reports on the expression of target genes. Therefore, the efficacy of the targeted therapies for canine HCC remains unclear.

Journal: BMC Research Notes
Funder: Japan Society for the Promotion of Science

New research uncovers hidden rules of immune response, opening doors for better vaccines and immunotherapies

Institute for Systems Biology
Peer-Reviewed Publication

Scientists at the Institute for Systems Biology (ISB) have uncovered key insights into how T cells – the body's frontline immune soldiers – respond to infections like COVID-19. These findings could help scientists refine immune response strategies to improve long-term protection against diseases. Furthermore, these insights could contribute to more precise treatments for cancer and autoimmune diseases.

Journal: Nature Communications

Breast cancers broadly defined by their genome architecture in Stanford Medicine study

Stanford Medicine
Peer-Reviewed Publication

Breast cancers at all stages are defined by the structure of their genomes, Stanford Medicine researchers find. Targeting these processes early is likely to offer unexpected therapeutic avenues.

Journal: Nature

Co-located cell types help drive aggressive brain tumors

Johns Hopkins Medicine
Peer-Reviewed Publication

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, according to new research led by investigators at the Johns Hopkins Kimmel Cancer Center Bloomberg~Kimmel Institute for Cancer Immunotherapy and the Johns Hopkins University School of Medicine.

Journal: Science
Funder: NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, NIH/National Institutes of Health, Neurosurgery Research Education Foundation, Bloomberg~Kimmel Institute for Cancer Immunotherapy, Mark Foundation For Cancer Research, Burroughs Wellcome Career Award for Medical Scientists, Commonwealth Foundation, Maryland Cigarette Restitution Fund and the NIH Pioneer Award